Presentation: 2B03

Expanding corporate compound files have defined our approach to HTS, driving the introduction of large-scale automated systems for primary screening and reagent production. Ideas of industrialization of R&D have raised the expectation of using standardized processes to shorten timelines and increase productivity. Although, applying a set of standard technologies has decreased the cycle time from assay development to screening, massive parallelization and 'industrialization' of processes is often hampered by the needs of highly specific projects. Biological performance is key to success, and targets requiring technologies not amenable to 1536 well formats still present problems. As a consequence of these bottlenecks and aided by the introduction of reliable benchtop equipment, we have seen a renaissance of workstation approaches. This presentation will cover strategies to enable resource, time and cost effective HTS, compare requirements for biochemical and cell-based HTS, and summarize the practical implementation of the different concepts at Pfizer, Sandwich.

Close Window X